Non-Oral Drug Delivery in Parkinson's Disease: Current Applications and Future
Küçük Resim Yok
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Galenos Publ House
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Parkinson's disease (PD) is a type of movement disorder that affects the ability to perform daily activities. It is considered that 1 million people in the U.S. and more than 10 million people worldwide live with PD. It is a chronic and progressive disease, so symptoms worsen over the time. Patients experience motor symptoms such as tremors, stiffness and slow motion, and non-motor symptoms such as sleep problems, constipation, anxiety, depression and fatigue. Dopaminergic drugs are critical for treating motor symptoms in PD. Levodopa (L-DOPA) is the gold standard medication for the control of motor symptoms. Because of the progression of the disease, the effectiveness of oral L-DOPA decreases over time and motor fluctuations such as delayed ON, no ON and unpredictable ON-OFF periods appear. These motor fluctuations affect the quality of life of the patient at a high rate and the patient has problems in fulfilling his daily morning routines. Gastrointestinal (GI) problems, as the common non-motor symptom, are the most important cause of motor fluctuations that occur because of inadequate oral treatment with the progression of PD. When oral treatments are not sufficient, non-oral treatments that are not affected by GI problems are required. In this review, the treatment strategies, developed and approved non-oral drug delivery systems in the early and advanced stages of PD are emphasized.
Açıklama
Anahtar Kelimeler
Parkinson's disease, oral and non-oral treatment, motor and non-motor fluctuations, Intestinal Bacterial Overgrowth, Oxidase Type-B, Double-Blind, Motor Complications, Nonmotor Symptoms, Gastrointestinal Dysfunction, Oropharyngeal Dysphagia, Clinical-Pharmacology, Comt Inhibitors, Levodopa
Kaynak
Turkish Journal of Pharmaceutical Sciences
WoS Q Değeri
N/A
Scopus Q Değeri
Q3
Cilt
19
Sayı
3
